Zobrazeno 1 - 10
of 32
pro vyhledávání: '"S. Chunduru"'
Autor:
Salah-Eddine Bentebibel, Willem W. Overwijk, Montaser Shaheen, Marc Uemura, Courtney W. Hudgens, Marihella James, Ravi Murthy, Gary C. Doolittle, Robert H.I. Andtbacka, Chantale Bernatchez, Michael A. Davies, S. Chunduru, Douglas B. Johnson, Daniel H. Johnson, Igor Puzanov, Patrick Hwu, Shah Rahimian, Cara Haymaker, Adi Diab, Joseph Markowitz, Denái R. Milton, Michael T. Tetzlaff, Sudhir Agrawal, Nashat Gabrail, Houssein Safa
Publikováno v:
Cancer Discov
Many patients with advanced melanoma are resistant to immune checkpoint inhibition. In the ILLUMINATE-204 phase I/II trial, we assessed intratumoral tilsotolimod, an investigational Toll-like receptor 9 agonist, with systemic ipilimumab in patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b6b8d46d46d9fa5dab66b18718b3d64
https://doi.org/10.1158/2159-8290.cd-20-1546
https://doi.org/10.1158/2159-8290.cd-20-1546
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Journal of Investigative Dermatology. 143:S265
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::094211d024e450e4eadb189586e21425
https://doi.org/10.1016/j.jid.2023.03.1561
https://doi.org/10.1016/j.jid.2023.03.1561
Autor:
Vivek Subbiah, Hans Minderman, Rolf Hultsch, Gregory Woodhead, Ravi Murthy, Shah Rahimian, Pete Anderson, Daniel Hendler, Igor Puzanov, Adi Diab, Charles Hennemeyer, Alain Algazi, Michal Lotem, Nadia Caplan, Jacob Schachter, Erkut Borazanci, C. Haymaker, Hani M. Babiker, S. Chunduru, Chantale Bernatchez
Publikováno v:
Annals of Oncology. 31:S711-S712
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3a8818db02f454c83618402bfe84fc47
https://doi.org/10.1016/j.annonc.2020.08.1151
https://doi.org/10.1016/j.annonc.2020.08.1151
Autor:
Hans Minderman, Shah Rahimian, S. Chunduru, Vivek Subbiah, Cara Haymaker, Adi Diab, Hani M. Babiker, Erkut Borazanci, G. Bindra, Orla Maguire, Peter M. Anderson, Chantale Bernatchez, I. Iverson, Igor Puzanov
Publikováno v:
Annals of Oncology. 30:v487
Background Tilsotolimod, a synthetic toll-like receptor 9 (TLR9) agonist, modulates the tumor immune microenvironment and has antitumor activity as monotherapy in preclinical models. In the ILLUMINATE-204 phase I/II study of tilsotolimod in combinati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4c35259ef7b9e5811628f2c3fdeb072
https://doi.org/10.1093/annonc/mdz253.021
https://doi.org/10.1093/annonc/mdz253.021
Autor:
Elena Schiopu, Namita Goyal, Tahseen Mozaffar, Kavita Y. Sarin, David Fiorentino, Youn H. Kim, K. Lees, S. Chunduru
Publikováno v:
Journal of Investigative Dermatology. 139:B18
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::00d4efb35bef31c131cbca58a9657521
https://doi.org/10.1016/j.jid.2019.06.082
https://doi.org/10.1016/j.jid.2019.06.082
Autor:
S. Chunduru, David H. Johnson, J. Geib, Cara Haymaker, Ravi Murthy, Patrick Hwu, Adi Diab, J. Markowitz, Robert H.I. Andtbacka, Suzanne Swann, Igor Puzanov, Chantale Bernatchez, Douglas B. Johnson, Marihella James, M. Shaheen, Shah Rahimian
Publikováno v:
Annals of Oncology. 29:viii442
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::56fa653eb10730e1e84d72044986c9b5
https://doi.org/10.1093/annonc/mdy289.001
https://doi.org/10.1093/annonc/mdy289.001
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Michael A. Davies, Hussein Abdul-Hassan Tawbi, Ravi Murthy, S. Chunduru, Marihella James, Rodabe N. Amaria, Scott E. Woodman, Willem W. Overwijk, Wen-Jen Hwu, Marc Uemura, Sudhir Agrawal, Patrick Hwu, Chantale Bernatchez, Jennifer A. Wargo, Isabella C. Glitza, Cara Haymaker, Sapna Pradyuman Patel, Adi Diab, Cassian Yee, Mark Cornfeld
Publikováno v:
Journal of Clinical Oncology. 35:136-136
136 Background: Checkpoint inhibitors (CPI) have transformed melanoma treatment but many patients remain refractory. CPI plus i.t. IMO may improve response by activating innate immune function. Based on this we initiated a trial of IMO in combination
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b50b8ad0f0d257e55f5eb2fa9472d301
https://doi.org/10.1200/jco.2017.35.7_suppl.136
https://doi.org/10.1200/jco.2017.35.7_suppl.136